摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-溴-2-(2-氟乙氧基)苯 | 132836-98-7

中文名称
1-溴-2-(2-氟乙氧基)苯
中文别名
——
英文名称
1-bromo-2-(2-fluoroethoxy)benzene
英文别名
2-Bromophenyl 2-fluoroethyl ether
1-溴-2-(2-氟乙氧基)苯化学式
CAS
132836-98-7
化学式
C8H8BrFO
mdl
——
分子量
219.053
InChiKey
UKXHGKXTSNUMLR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    1-溴-2-(2-氟乙氧基)苯 在 palladium on activated charcoal 正丁基锂氢气甲基磺酰氯三乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, -78.0~20.0 ℃ 、310.27 kPa 条件下, 反应 21.0h, 生成 tert-butyl 4-(2-(2-fluoroethoxy)phenyl)piperidine-1-carboxylate
    参考文献:
    名称:
    (Phenylpiperidinyl)cyclohexylsulfonamides: Development of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)
    摘要:
    Although alpha(1), adrenergic receptor blockers can be very effective for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), their usage is limited by CV-related side-effects that are caused by the subtype non-selective nature of the current drugs. To overcome this problem, it was hypothesized that a alpha(1a/1d) subtype selective antagonist would bring more benefit for the therapy of BPH/LUTS. In developing such selective alpha(1a/1d) ligands, a series of (phenylpiperidinyl)cyclohexylsulfonamides has been synthesized and evaluated for binding to three cloned human alpha(1)-adrenergic receptor subtypes. Many compounds showed equal affinity for both alpha(1a) and alpha(1d) subtypes with good selectivity versus the alpha(1b) subtype. (C) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.04.098
  • 作为产物:
    描述:
    2-溴苯酚对甲苯磺酸氟乙酯potassium carbonate 作用下, 以 乙腈 为溶剂, 反应 16.0h, 以100%的产率得到1-溴-2-(2-氟乙氧基)苯
    参考文献:
    名称:
    有效的基于3-benzazepine的GluN2B受体拮抗剂的4-苯基丁基侧链的修饰。
    摘要:
    NMDA受体过度活化驱动的兴奋性毒性代表了急性和慢性神经系统疾病和神经退行性疾病的主要机制。与NMDA受体的艾芬地尔结合位点相互作用的负变构调节剂能够中断这一正在进行的神经损伤过程。从有效的3-苯并ze庚因-1,7-二醇4a开始,通过修饰N-(4-苯基丁基)侧链设计了新型NMDA受体拮抗剂。关于开发新型氟化PET示踪剂,合成了区域异构的氟乙氧基衍生物11、12、14和15。通过Sonogashira反应和亲核取代制备在N-侧链末端具有各种杂芳基部分的类似物19和20。通过1,3-偶极环加成获得氟乙基三唑37。在几个新的配体中 (杂)芳基丁基侧链的柔韧性受到三键结合的限制。在已确定的竞争性分析中,使用[3H]芬苯甲腈作为放射性配体,测试了对苯丙草胺结合位点的亲和力。在末端苯环上引入氟乙氧基部分,用杂芳基环取代末端苯环,并将三键结合到丁基间隔基中,导致GluN2B亲和力大大降低。在末端苯环上带有对氟乙氧基部分的苯酚15(Ki
    DOI:
    10.1016/j.bmc.2019.06.035
点击查看最新优质反应信息

文献信息

  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
    申请人:Novartis AG
    公开号:US20210115065A1
    公开(公告)日:2021-04-22
    The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.
    本发明提供了化合物(Ia)的结构或其药学上可接受的盐; 一种制造本发明化合物的方法,固体形式,药理活性剂的组合,药物组合物以及使用这些化合物和固体形式来治疗或预防寄生虫病,例如疟疾的方法。
  • Process for producing 1,2-dialkoxy-3-fluorobenzene
    申请人:Qiu Mingjian
    公开号:US20090227817A1
    公开(公告)日:2009-09-10
    The present invention relates to a process for producing a 2-fluoro-6-halophenol as an intermediate; a process for producing a 2-alkoxy-3-fluorophenol and further a 1,2-dialkoxy-3-fluorobenzene from the 2-fluoro-6-halophenol; a second process for producing a 1,2-dialkoxy-3-fluorobenzene from the 2-fluoro-6-halophenol; and a 2-alkoxy-3-fluorophenol. The 2-fluoro-6-halophenol can be obtained using a 2-fluorophenol as a starting material and through a sulfonation reaction, a halogenation reaction, and a deprotection reaction. The 2-fluoro-6-halophenol is alkyl-etherified, and subsequently the halogen atom is converted into a hydroxyl group to obtain the 2-alkoxy-3-fluorophenol, which is further alkyl-etherified to thereby obtain the 1,2-dialkoxy-3-fluorobenzene. Alternatively, a 1,2-dialkoxy-3-fluorobenzene is also obtained by converting the halogen atom of the 2-fluoro-6-halophenol into a hydroxyl group to thereby form 3-fluorocatechol and subsequently alkyl-etherifying two hydroxyl groups thereof. The processes of the invention realize low production costs and high process yields, and thus are suitable for industrial production of a 1,2-dialkoxy-3-fluorobenzene.
    本发明涉及一种生产2-氟-6-卤苯酚作为中间体的过程;一种从2-氟-6-卤苯酚生产2-烷氧基-3-氟苯酚,进而从中生产1,2-二烷氧基-3-氟苯的过程;一种从2-氟-6-卤苯酚生产1,2-二烷氧基-3-氟苯的第二过程;以及2-烷氧基-3-氟苯酚。可以使用2-氟苯酚作为起始原料,通过磺化反应、卤代反应和去保护反应获得2-氟-6-卤苯酚。将2-氟-6-卤苯酚烷基醚化,随后将卤原子转化为羟基以获得2-烷氧基-3-氟苯酚,进一步烷基醚化以获得1,2-二烷氧基-3-氟苯。另外,通过将2-氟-6-卤苯酚的卤原子转化为羟基从而形成3-氟邻苯二酚,随后烷基醚化两个羟基,也可以获得1,2-二烷氧基-3-氟苯。本发明的工艺实现了低生产成本和高工艺产率,因此适用于工业生产1,2-二烷氧基-3-氟苯。
  • Pesticidal 2-fluoroethyl ethers
    申请人:FMC Corporation
    公开号:US04960884A1
    公开(公告)日:1990-10-02
    Pesticidal mono-, di-, and tri-2-fluoroethyl ethers of the formula R.sup.1 R.sup.2.sub.m Ar(OCH.sub.2 CH.sub.2 F).sub.n, compositions thereof and their insecticidal, acaricidal and nematicidal uses are described and claimed.
    描述和声明了化学式为R.sup.1 R.sup.2.sub.m Ar(OCH.sub.2 CH.sub.2 F).sub.n的杀虫单、二和三-2-氟乙基醚,以及它们的组合物及其杀虫、杀螨和杀线虫用途。
  • P2X7 MODULATORS
    申请人:Janssen Pharmaceutica NV
    公开号:US20150322062A1
    公开(公告)日:2015-11-12
    The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    本发明涉及公式(I,IIa和IIb)的化合物:本发明还涉及包括公式(I,IIa和IIb)的化合物的制药组合物。制备和使用公式(I,IIa和IIb)的方法也在本发明的范围内。
  • P2X7 modulators
    申请人:Janssen Pharmaceutica NV
    公开号:US09066946B2
    公开(公告)日:2015-06-30
    The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    本发明涉及公式(I、IIa和IIb)的化合物。本发明还涉及包含公式(I、IIa和IIb)的药物组成物。制备和使用公式(I、IIa和IIb)化合物的方法也在本发明的范围内。
查看更多